Microbot Medical Announces Appointment of Chief Technology Officer
April 05 2018 - 4:01PM
Microbot Medical Inc. (NASDAQ:MBOT), a medical device company
specializing in the design and development of transformational
micro-robotic medical technologies, today announced the appointment
of Mr. Simon Sharon as Chief Technology Officer, effective
immediately. In his role, Mr. Sharon will report directly to
Harel Gadot, Microbot’s Chief Executive Officer, President and
Chairman, and resume the role previously held by the VP of R&D,
who recently stepped down to pursue other endeavors. Mr. Sharon had
previously served as the Chairman of Microbot’s Scientific Advisory
Board.
“During the current quarter, our goals are to
complete the two ongoing studies related to our first product, the
Self-Cleaning Shunt (SCS), and to close the previously announced
acquisition of CardioSert,” commented Mr. Gadot. “In addition, as
we continue to explore additional strategic opportunities, it is
imperative that we strengthen Microbot’s development team to ensure
we meet our development milestones and expand our portfolio. I’m
confident that Simon’s knowledge of our current development and our
unique technology platforms, coupled with his exceptional
operational expertise over portfolios of R&D projects, will be
extremely valuable as we aim to achieve key milestones over the
next few quarters.”
Mr. Sharon is a seasoned medical device
executive with over 30 years of industry experience. Prior to
rejoining Microbot, Simon served as the Chief Technology Officer at
MEDX Xelerator, an Israel-based medical device and digital health
incubator with partners such as Boston Scientific Corporation and
Intellectual Ventures. He was also the Chairman of the Scientific
Board at XACT Robotics, a private Israeli company developing a
novel platform robotic technology for needle steering in minimally
invasive interventional procedures. Prior to this, Mr. Sharon held
the position of Chief Operating Officer at Microbot Medical Ltd.
before it became a publicly traded company. Prior to joining
Microbot in 2013, Mr. Sharon was the Vice President of Research
& Development with IceCure Medical, a TASE traded company
developing a portfolio of cryogenic ablation systems. Prior to
IceCure, he held roles of increasing responsibility at Rockwell
Automation–Anorad Israel Ltd, a leading linear motor-based,
precision positioning equipment manufacturer. Prior to
Rockwell, Simon was the Research & Development Manager at
Disc-O-Tech Medical Technologies Ltd., a private orthopedic venture
that was acquired by Kyphon (currently part of Medtronic), and
before this was the Research & Development Manager at CI
Systems, a worldwide supplier of a wide range of electro-optical
test and measurement equipment.
About Microbot Medical, Inc.
Microbot was founded in 2010, which commenced
operations in 2011, and became a NASDAQ listed company on November
28, 2016. The Company specializes in transformational micro-robotic
medical technologies leveraging the natural and artificial lumens
within the human body. Microbot’s current platforms, ViRob and
TipCAT, are comprised of two highly advanced micro-robotic
technologies, from which the Company is currently developing its
first two product candidates: the Self Cleaning Shunt, or SCS, for
the treatment of hydrocephalus and Normal Pressure Hydrocephalus,
or NPH; and a self-propelling, semi-disposable endoscope that is
being developed initially for use in colonoscopy procedures.
Further information about Microbot Medical is available at
http://www.microbotmedical.com.
The ViRob technology is a revolutionary
autonomous crawling micro-robot which can be controlled remotely or
within the body. Its miniature dimensions allow it to
navigate and crawl in different spaces within the human body,
including blood vessels, the digestive tract and the respiratory
system. Its unique structure gives it the ability to move in
tight spaces and curved passages as well as the ability to remain
within the human body for prolonged time. To learn more about
ViRob please visit
http://www.microbotmedical.com/technology/virob/.
TipCAT is a transformational self-propelled,
flexible, and semi-disposable endoscope providing see & treat
capabilities within tubular lumens in the human body such as the
colon, blood vessels, and the urinary tract. Its locomotion
mechanism is perfectly suitable to navigate and crawl through
natural & artificial tubular lumens, applying the minimal
necessary pressure to achieve the adequate friction required for
gentle, fast, and safe advancement within the human body. To
learn more about TipCAT visit
http://www.microbotmedical.com/technology/tipcat/.
Safe Harbor
Statements pertaining to future financial and/or
operating results, future growth in research, technology, clinical
development, and potential opportunities for Microbot Medical Inc.
and its subsidiaries, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management constitute forward-looking statements. Any statements
that are not historical fact (including, but not limited to
statements that contain words such as “will,” “believes,” “plans,”
“anticipates,” “expects” and “estimates”) should also be considered
to be forward-looking statements. Forward-looking statements
involve risks and uncertainties, including, without limitation,
risks inherent in the development and/or commercialization of
potential products, the outcome of its further evaluation of the
CardioSert technology, uncertainty in the results of clinical
trials or regulatory approvals, need and ability to obtain future
capital, and maintenance of intellectual property rights. Actual
results may differ materially from the results anticipated in these
forward-looking statements and as such should be evaluated together
with the many uncertainties that affect the businesses of Microbot
Medical Inc. particularly those mentioned in the cautionary
statements found in Microbot Medical Inc.’s filings with the
Securities and Exchange Commission. Microbot Medical disclaims any
intent or obligation to update these forward-looking
statements.
Investor Contacts:
Analysts and Institutional InvestorsMichael
PolyviouEVC Groupmpolyviou@evcgroup.com 732-232-6914
Individual InvestorsJeremy RoeIntegra
Consulting Group llcjeremy@integracg.net (925) 262-8305
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Apr 2023 to Apr 2024